Toward effective targeted therapy for the treatment of adult acute lymphoblastic leukemia
暂无分享,去创建一个
[1] X. Thomas,et al. Antibody‐based therapies in B‐cell lineage acute lymphoblastic leukaemia , 2015, European journal of haematology.
[2] J. Radich,et al. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia , 2014, British journal of haematology.
[3] L. Hoffman,et al. Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications , 2014, Front. Oncol..
[4] T. Clackson,et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. , 2013, The New England journal of medicine.
[5] B. Quesnel,et al. Administration of alemtuzumab and G‐CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study , 2013, European journal of haematology.
[6] R. Larson,et al. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome—positive acute lymphoblastic leukemia , 2013, Leukemia.
[7] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[8] A. Spyridonidis,et al. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] R. Larson,et al. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] H. Kantarjian,et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. , 2012, The Lancet Oncology.
[11] R. Lutz,et al. SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies , 2011, Clinical Cancer Research.
[12] M. Andreeff,et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Larson,et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study , 2010, American journal of hematology.
[14] H. Dombret,et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Schuler,et al. Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention , 2009, Leukemia & lymphoma.
[16] D. Hoelzer,et al. Treatment of adult acute lymphoblastic leukemia. , 2009, Seminars in hematology.
[17] A. Ferrando,et al. Inhibition of NOTCH1 Signaling and Glucocorticoid Therapy in T-ALL , 2008 .
[18] T. Naoe,et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Je-Hwan Lee,et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia , 2005, Leukemia.
[20] Sante Tura,et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.
[21] J. Nomdedéu,et al. Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia , 2001, Bone Marrow Transplantation.
[22] J. Thorson,et al. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. , 2000, Current pharmaceutical design.